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Estimation and interpretation of thyroid function tests in pregnant women is of utmost importance for maternal, fetal and
neonatalhealth.Ourobjectivewastocalculatelaboratory-andgeography-speciﬁcreferenceintervalsforthyroidhormonesduring
pregnancy in an iodine-suﬃcient area of the Mediterranean, Crete, Greece. This project was performed in the context of “Rhea”
mother-child cohort. Fulﬁllment of extensive questionnaires and estimation of free triiodothyronine (fT3), free thyroxine (fT4),
thyroid-stimulating hormone (TSH), and antithyroid antibodies were performed. The reference population was deﬁned using
inclusion criteria regarding thyroidal, obstetric, and general medical status of women. Reference interval for TSH was 0.05–
2.53μIU/mL for the ﬁrst and 0.18–2.73μIU/mL for the second trimester. 6,8% and 5,9% of women in the ﬁrst and second
trimester, respectively, had TSH higher than the upper reference limit. These trimester-speciﬁc population-based reference ranges
are essential in everyday clinical practice for the correct interpretation of thyroid hormone values and accurate classiﬁcation of
thyroid disorders.
1.Introduction
Pregnancy is a period of signiﬁcant hormonal changes and
metabolic demands which result in complex eﬀects on thy-
roid function [1–3]. More speciﬁcally, alterations in iodine
metabolism [1], production of β-chorionic gonadotropin
(β-hCG), and increases in both thyroid hormone-binding
proteins and thyroid hormones per se [4, 5]a r es o m eo f
thephysiologicchangesthatoccurduringnormalpregnancy.
At the same time, thyroid hormones play a critical role
in neonatal and child neurodevelopment [6], and mater-
nal thyroid disorders can lead to obstetric complications
and irreversible eﬀects on the fetus [7]. These ﬁndings point
out the need for all pregnant women to be screened for
thyroid disorders with a valid biomarker with distinct ref-
erence ranges.
In the past years, a number of studies from diﬀerent re-
gions have developed reference ranges for thyroid hormones
during pregnancy women [8–31]; however these results
should not be extrapolated due to diﬀerences in ethnicity, io-
dine intake, and immunometric assay applied in each study.
Moreover, the methodology used for the determination of
the reference population (choice of reference population,
sample size, assessment of outliers) diﬀe r sa c r o s ss t u d i e s
resulting in a variation of absolute reference limits.
The aim of this study was to develop laboratory- and ge-
ography-speciﬁc reference intervals for thyroid hormones2 Journal of Thyroid Research
(thyroid-stimulating hormone (TSH),and freetriiodothyro-
nine (free T3), free thyroxine (free T4)) during pregnancy in
aniodine-suﬃcientareaoftheMediterranean,Crete,Greece.
2.MaterialsandMethods
2.1. Study Population. This project utilized data from the
Rhea mother-child cohort, in the island of Crete, Greece.
The mother-child “Rhea” study is a prospective cohort study
examining a population sample of pregnant women and
their children in a prefecture of southern Greece. Pregnant
women, who became pregnant within one year, starting
February 2007, participated in the study. The ﬁrst contact
was done at the time of the ﬁrst major ultrasound, and
women were divided in trimesters of pregnancy, according
togestationalagewhichwasdeﬁnedbylastmenstrualperiod
and ultrasound (ﬁrst: <13 weeks, second: 13–27 weeks, and
third trimester: >28 weeks). Participants were interviewed,
and blood samples were collected and stored in −80◦C. Ex-
tensive questionnaires were completed, and standardized in-
formation from ultrasounds was collected together with data
from clinical records during pregnancy and birth. The study
was approved by the corresponding ethical committees, and
all participants provided written informed consent.
From the entire population of the Rhea cohort (n =
1610), all available serum samples were analyzed for thyroid
hormone measurements (n = 1300). According to the rec-
ommendations of the National Academy of Clinical Bio-
chemistry (NACB) [32], we subsequently excluded women
with a self-reported thyroidal dysfunction (goiter, cancer,
hyper-, and hypo-thyroidism), a laboratory diagnosis of
overt hypo- or hyperthyroidism (i.e., abnormal values of
TSH and FT4 using the reference ranges of the assay used),
evidence for autoimmune thyroid disease (elevated anti-
TPO and anti-Tg), past or present use of thyroid medica-
tions, parental history of any thyroid illness, and women
with incomplete information regarding thyroid function. In
addition, women with multiple or complicated pregnancies
(hyperemesis, gestational diabetes or hypertension, perinatal
infections, and stillbirths), clinical diagnosis of a chronic
or autoimmune disease (diabetes, hypertension, asthma, in-
ﬂammatory bowel disease, tumors, and others), and a past
historyofspontaneousabortionswerealsoremovedfromthe
reference population (Figure 1).
2.2. Laboratory Analysis. For each sample, TSH, free thyrox-
ine(freeT4),freetriiodothyronine(freeT3),andantithyroid
antibodies (antithyroperoxidase [anti-TPO] and antithy-
roglobulin [anti-Tg]) were measured by IMMULITE 2000
immunoassay system (Siemens Healthcare Diagnostics, ILL
60015-0778, USA). For TSH, inter- and intra-assay vari-
ability were <5.3% and <6.4%, respectively, for levels of
0.32–39mIU/mL. Accordingly, for free T4 these values were
<7.8% and <7.1% for the level of 0.51–4.82ng/dL (6.56–
62.03pmol/L), for free T3 < 9.1% & <10% for the level of
2.5–13pg/mL (3.84–19.96pmol/L), for anti-Tg < 4.9% and
<5.8%, and for anti-TPO < 7.4% and 7.2%. The proposed
reference limits of the manufacturer for normal euthyroid
adults were: free T3: 1.8–4.2pg/mL (2.76–6.45pmol/L),
free T4: 0.89–1.76ng/dL (11.5–22.7pmol/L), and TSH: 0.4–
4μIU/mL. Anti-TPO and anti-Tg were considered elevated if
levels were ≥35IU/mL and >40IU/mL, respectively.
2.3.StatisticalAnalysis. Alldatawer eanalyzedb ySPSS17for
windows. The nature of the underlying distribution of free
T3, free T4, and TSH for the reference population was ex-
amined by inspecting normality tests, histograms and P-
plots. In case of a signiﬁcant variation from normal distri-
bution, a logarithm transformation (log and ln) was applied
to achieve normality. Outliers were identiﬁed using box
plots. For the identiﬁed outliers Dixon’s Q test was applied
to the least extreme; if the test rejects the least extreme
outlier, then the more extreme outliers are also rejected.
Continuously, when the data followed a Gaussian distri-
bution or were transformed to a normal distribution, ref-
erence intervals were computed as follows: mean ± 1.96 ×
standard deviation. If normality was not achieved, even after
transformation or after the outlier deletion, a nonparametric
method was applied to estimate the reference intervals, by
computing the rank numbers of 2.5th and the 97.5th per-
centiles to estimate the lower and the higher limits of the ref-
erence interval, respectively.
Thyroid hormones were expressed as mean, median,
standard deviation, 2.5th and 97.5th percentile for the 1st
and 2nd trimester. The Mann-Whitney U test was used to
compare diﬀerences for the 2 trimesters for a level of sig-
niﬁcance of P<0.05.
3. Results
3.1.TotalStudyPopulation. Startingfromatotalcohortpop-
ulation of 1610 pregnant women, 1300 samples were avail-
able for thyroid function and antibody analyses. Of them,
35.2% were in the ﬁrst (<13 weeks), 61% in the second
(13–27 weeks), and 3.7% in the third trimester (>28 weeks)
of pregnancy (Table 1). The age of the mothers varied
from 15 to 45 years, and the majority of mothers were of
Greek origin (85.3%). History of spontaneous miscarriages
was present in 223 women (17.2%). Considering thyroid
function, 389 (29.9%) of mothers had a positive family
history of thyroidal disease, while 165 (12.7%) and 87
(6.7%) women had elevated levels of anti-TPO and anti-TG
antibodies, respectively.
3.2.ReferencePopulation. Afterimplementationoftheafore-
mentioned exclusion criteria, a total of 875 women were
excluded from the study (Figure 1, Table 1), resulting to a
ﬁnal population of 425 women (1st trimester: 143, 2nd
trimester: 260, 3rd trimester: 22). Women in the third
trimester (n = 22) were excluded from the analysis, since
the sample size was not adequate for the estimation of
reference intervals to a reasonable degree of precision. The
ﬁnal population (403 women) was used to determine the
reference limits and the 95% conﬁdence intervals for TSH,
free T4, and free T3 for the ﬁrst and second trimester of
pregnancy.Journal of Thyroid Research 3
1610 women included in Rhea study
875 excluded
Thyroid disorders
1300 available biological samples
Reference population: 425 women
1st trimester:
143 women
2nd trimester:
260 women
3rd trimester:
22 women
Excluded: Inadequate sample size
￿ Positive antithyroid antibodies (n = 197)
￿ Self-reported thyroid diseases (n = 242)
￿ Overt hypo-/hyperthyroidism (n = 8)
￿ Thyroid medications (n = 148)
￿ Positive parental history (n = 389)
￿ Incomplete information (n = 68)
Multiple pregnancies (n = 37)
Maternal chronic diseases (n = 107)
History of spontaneous abortions (n = 223)
Pregnancy complications (n = 113)
Abortions and stillbirths (n = 27)
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Figure 1: Flow diagram of the study process for the determination of the reference population.
Table 1: Demographic data for pregnant women in total and reference study population.
Total study populationa Reference population
1st trimester 2nd trimester 3rd trimester 1st trimester 2nd trimester
Sample size (n) 458 794 48 143 260
Age (years)b 29.16 (5.12) 28.98 (5.19) 28.37 (4.61) 28.50 (5.09) 27.79 (4.95)
Greek origin n (%) 369 (80.6) 698 (87.9) 42 (87.5) 114 (79.7) 221 (85)
aWomen with available biological samples.
bValues are expressed as mean (SD).
3.3. Reference Values for Thyroid Hormones. Figure 2 shows
the box plots for TSH, free T3, and free T4 for ﬁrst and
second trimester after the outlier assessment. Additionally,
mean values, standard deviations, medians, and the 2.5th
and 97.5th percentiles for all thyroid hormones according to
trimester are shown in Table 2.
According to our results (Tables 2 and 3), the refer-
ence intervals of serum TSH levels for the ﬁrst trimester
were 0.05–2.53μIU/mL, of free T3 1.54–5.22pg/mL (2.37–
8.02pmol/L), and of free T4 0.95–1.53ng/dL (12.23–
19.69pmol/L). For the second trimester, respective reference
intervals were: 0.18–2.73μIU/mL for TSH, 1.78–5.29pg/mL
(2.73–8.13pmol/L) for free T3, and 0.87–1.45ng/dL (11.20–
18.66pmol/L) for free T4. Median TSH and free T3 values
showed a slight increase in 2nd trimester, while median free
T4 values fell as gestational age advanced.
Mann Whitney U test revealed signiﬁcant diﬀerences be-
tween trimesters for free T4 (P value < 0.001), while re-
spective P values for TSH and free T3 were 0.058 and 0.054.
These ﬁndings justify the separation of groups into diﬀerent
trimesters (Table 2, Figure 2).4 Journal of Thyroid Research
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Figure 2: Box plot of TSH, free T3, and free T4 concentrations in the reference population during the 1st and 2nd trimester of gestation.
TSH: thyroid-stimulating hormone; Free T3: free triiodothyronine; free T4: free thyroxine Diﬀerences between ﬁrst and second trimester are
shown with P values (P = 0.058 for TSH, P = 0.054 for free T3, P<0.001 for free T4).
As shown in Table 4, if the reference limits of the man-
ufacturer were applied to our entire cohort, misclassiﬁcation
of maternal thyroid clinical entities would occur. More
speciﬁcally, 47 and 43 women with TSH concentrations that
are normal for the ﬁrst and second trimester, respectively
would have been misclassiﬁed as having subclinical hy-
perthyroidism. Conversely, 25 and 29 women with a TSH
above the ﬁrst and second trimester-speciﬁc upper reference
limit would not have been identiﬁed as subclinical hypothy-
roidism.
4. Discussion
During pregnancy several hormonal changes and metabolic
demands occur, resulting in complex eﬀects on thyroid func-
tion [3]. Alterations in the pituitary-thyroid axis include an
increase in thyroid hormone-binding globulin along with
increases in total T4, T3 as well as serum thyroglobulin (TG).
Additionally, iodine clearance by the kidneys is enhanced
during gestation, while the mild thyrotropic eﬀects of rising
β-hCG may exert negative feedback on TSH secretion [33]
wrongly suggesting hyperthyroidism in normal pregnant
women of the 1st trimester [1].
The incidence of overt and subclinical hypothyroidism
in pregnant women has been estimated to be around 0.3–
0.5 and 2-3%, respectively [34]. Recent studies have shown
that untreated hypothyroidism during pregnancy increases
the incidence of maternal anemia, preeclampsia, postpartum
hemorrhage, placental abruption, and spontaneous abortion
and may cause low birth weight, prematurity, congenital
malformations, and impaired fetal brain development withJournal of Thyroid Research 5
Table 2: Thyroid hormones according to gestational age, Rhea mother-child cohort, Crete, Greece.
N Distribution 2.5th percentiles 97.5th percentile Median Mean SD Reference range
1st trimester
TSHa μIU/mL 141 Not normal 0.05 2.53 1.02 1.08 0.61 0.05–2.53
free T3b pg/mL (pmol/L)141 Normald 1.84 (2.83) 5.39 (8.28) 3.21 (4.93) 3.38 (5.19) 0.94 (1.44) 1.54–5.22
(2.37–8.02)
free T4c ng/dL (pmol/L) 139 Normale 0.96 (12.36) 1.60 (20.59) 1.24 (15.96) 1.24 (15.96) 0.15 (1.93) 0.95–1.53
(12.23–19.69)
2nd trimester
TSHa μIU/mL 257 Not normal 0.18 2.73 1.14 1.23 0.65 0.18–2.73
free T3b pg/mL (pmol/L) 256 Normal 1.99 (3.06) 5.30 (8.14) 3.52 (5.41) 3.55 (5.45) 0.87 (1.34) 1.78–5.29
(2.73–8.13)
free T4c ng/dL (pmol/L) 258 Normal 0.84 (10.81) 1.44 (18.53) 1.16 (14.93) 1.16 (14.93) 0.15 (1.93) 0.87–1.45
(11.20–18.66)
TSH: thyroid-stimulating hormone; free T3: free triiodothyronine; free T4: free thyroxine.
aDiﬀerence between ﬁrst and second trimester: P = 0.058.
bDiﬀerence between ﬁrst and second trimester: P = 0.054.
cDiﬀerence between ﬁrst and second trimester: P<0.001.
dAfter outlier deletion and log transformation.
eAfter outlier deletion.
Table 3: Comparison between reference ranges for thyroid hormones as calculated by our analysis and those proposed by the manufacturer.
Reference ranges TSH (μIU/mL) free T4 (ng/dL) free T3 (pg/mL)
1st trimester 2nd trimester 1st trimester 2nd trimester 1st trimester 2nd trimester
Rhea cohort 0.05–2.53 0.18–2.73 0.95–1.53 0.87–1.45 1.54–5.22 1.78–5.29
Manufacturer 0.4–4 0.89–1.76 1.8–4.2
TSH: thyroid-stimulating hormone; free T3: free triiodothyronine; free T4: free thyroxine.
Table 4: Thyroid clinical entities in the general population of Rhea mother-child cohort based on: (i) the manufacturer’s and (ii) the derived
reference limits.
Trimester Reference
limits
Normal thyroid
function n (%)a
Subclinical
hypothyroidism
n (%)b
Clinical
hypothyroidism
n (%)c
Subclinical
hyperthyroidism
n (%)d
Clinical hyper-
thyroidism n
(%)e
1st Manufacturer 386 (84.3) 6 (1.3) 0 (0) 48 (10.5) 7 (1.5)
Rhea cohort 371 (81.0) 31 (6.8) 0 (0) 1 (0.2) 10 (2.2)
2nd Manufacturer 680 (86.6) 18 (2.3) 1 (0.1) 61 (7.7) 1 (0.1)
Rhea Cohort 653 (82.2) 47 (5.9) 0 (0) 18 (2.3) 9 (1,1)
aTSH between reference limits and free T4 between reference limits.
bTSH over the upper limit of reference limits and free T4 between reference limits.
cTSH over the upper limit of reference limits and free T4 under the lower limit of reference limits.
dTSH under the lower limit of reference limits and free T4 between reference limits.
eTSH under the lower limit of reference limits and free T4 over the upper limit of reference limits.
decreased intelligence quotient (IQ) of children [35]. Con-
versely,hyperthyroidismhasbeendescribedinabout0.2%of
womenduringpregnancy[36]andmayleadtopreeclampsia,
stillbirths, preterm delivery, intrauterine growth retardation,
and low birth weight [7]. Withstanding the above, the serial
changes in serum thyroid hormone levels imply the need to
better deﬁne “pregnancy-speciﬁc” normative reference ran-
ges for thyroid function tests for early diagnosis of hyper-
and hypothyroidism during pregnancy.
Our study represents the ﬁrst study performed in a Med-
iterranean area, the island of Crete, within an iodine-suf-
ﬁcient country, Greece [37]. It provides reference ranges for
thyroid hormones during the ﬁrst and second trimester of
pregnancy. International guidelines recommend determin-
ing serum TSH as the ﬁrst-line screening variable for thyroid
dysfunction before conception [38] and during pregnancy
[3, 39]. According to our results and in agreement with
previous studies [40], the derived reference intervals for TSH
were diﬀerent (narrower and lower) from those proposed
by the manufacturer. More speciﬁcally, our TSH reference
intervals were 0.05–2.53 and 0.18–2.73μIU/mL for the
ﬁrst trimester and second trimester, respectively, compared6 Journal of Thyroid Research
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to 0.4–4μIU/mL. Consequently, women with subclinical
hypothyroidism would not have been identiﬁed, and normal
women would have been misclassiﬁed as having subclinical
hyperthyroidism if the manufacturer’s TSH limits were used.
Regarding free T4, and free T3, our intervals were only
slightly diﬀerent.
Many cross-sectional studies have reported trimester-
speciﬁc referenceranges for free T3, free T4, and TSH among
pregnant women [8–31]. However these reported reference
ranges vary due to diﬀerences in ethnicity, iodine in-
take, sample size, assessment of reference population, and
immunometric assay used among studies. Table 5 summa-
rizes 1st and 2nd trimester-speciﬁc reference intervals for
thyroid hormones from 21 studies worldwide. Ethnic dispar-
ities along with variations in iodine nutrition characteristics
result in geographic variability of hormonal values. In ad-
dition, diﬀerent reagents used by laboratories recognize dis-
tinct circulating TSH isoforms with resulting ﬂuctuations
even for the same sample [41]. Therefore, there is a growing
need for laboratory- and geography- speciﬁc reference inter-
vals [42]. Moreover, the methodology used by the published
studies to date varies in terms of inclusion criteria for the
determination of reference population, sample size, and
assessment of outliers. More speciﬁcally, most studies used
nonparametric methods in order to provide reference inter-
vals without reporting the underlying distribution [10, 12,
14, 19], did not mention whether outliers were detected
and removed [10–20] ,a n dm o s ti m p o r t a n t l y ,i ns o m e
cases, have not applied strict criteria to obtain a well-
deﬁned healthy population [13, 14, 16, 17]. According to
the National Academy of Clinical Biochemistry (NACB) [32]
and the National Health and Nutrition Examination Survey
(NHANES), this well-deﬁned healthy population should be
based on speciﬁc exclusion criteria and represents the most
important prerequisite for the determination of reference
intervals [43, 44].
Based on the above, we selected our reference population
from a large pool of Rhea mother-child cohort in Crete, after
implementationofstringentcriteria.Initially,weexcludedall
mothers with any kind of thyroid abnormality since women
positiveforthyroidautoantibodiestypicallyhavehigherTSH
values and therefore aﬀectandskewtheupperreferencelimit
[45, 46]. In addition, women with twin pregnancies or with
hyperemesis gravidum were also removed from the reference
population due to their potential for low TSH values (higher
serum hCG) and interference with the lower limit of TSH
reference range [22, 47, 48]. Based on the association
between autoimmunity and thyroid dysfunction [49], we
also excluded mothers with positive history of autoimmune
diseases. The ﬁnal strictly deﬁned reference population of
403 women was considered adequate for the estimation of
reference intervals fulﬁlling the sample size requirements
of Clinical Laboratory Standards (NCCLS) [43]. Additional
methodological strengths of our study include examination
of distributions and respective application of parametric or
nonparametric methods, assessment of outliers, and use of a
statistical test to resolve whether separate reference intervals
should be calculated for the ﬁrst and second trimester.
Results from this test conﬁrmed the need for trimester-spe-
ciﬁc reference ranges in agreement to the existing literature
and as indicated by normal physiology.
Our study is limited by lack of data concerning the third
trimester. Pregnant women were partitioned into trimesters
upon entering the study, and thus the resulting sample size
(n = 22) was not adequate for the estimation of reference
intervals to a reasonable degree of precision. However,
during the second half of gestation TSH levels return to pre-
pregnancy levels and remain stable [50]. In addition, there
w a so n l yas m a l ln u m b e ro fw o m e n( n = 12) in less than
8 weeks of gestation, when hCG has a minimal eﬀect on
thyroid. Contrary to The National Health and Nutrition
Examination Survey in the USA [36], some studies propose
that thyroid ultrasound should be used as an additional
exclusion criterion to rule out thyroid pathology [51]. In
our study, we did not include thyroid ultrasound for the
detection of goiter or presence of hypoechogenicity and
nodularity of thyroid, since these data were not collected.
Finally, an important limitation is the assumption of iodine
suﬃciency in all women, as we did not evaluate iodine status
by urine iodine estimation. However, median urinary iodine
excretion (the best parameter to evaluate the adequacy of
iodine nutrition in a population) during the last two decades
i nG r e e c eh a sb e e ne s t i m a t e dt ob eo v e r2 0 0μg/g Cr [52, 53],
which is well within normal limits [54]. These ﬁndings in-
dicate that, at present, Greece may be considered as an io-
dine-suﬃcient country.
5. Conclusion
DatafromthisstudyestablishreferencevaluesforGreekCre-
tan pregnant women and point out the need for laboratory-
and geography-speciﬁc reference ranges in an eﬀort to detect
overt and subclinical thyroid disorders and to evaluate the
risk for both obstetric complications and impaired fetal
development.
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